Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

132 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sweat chloride reflects CFTR function and correlates with clinical outcomes following CFTR modulator treatment.
Zemanick ET, Ramsey B, Sands D, McKone EF, Fajac I, Taylor-Cousar JL, Mall MA, Konstan MW, Nair N, Zhu J, Arteaga-Solis E, Van Goor F, McGarry L, Prieto-Centurion V, Sosnay PR, Bozic C, Waltz D, Mayer-Hamblett N. Zemanick ET, et al. Among authors: mayer hamblett n. J Cyst Fibros. 2025 Jan 3:S1569-1993(24)01854-X. doi: 10.1016/j.jcf.2024.12.006. Online ahead of print. J Cyst Fibros. 2025. PMID: 39755444 Free article.
What does it mean to be "healthy" when taking elexacaftor/tezacaftor/ivacaftor (ETI)? A qualitative study.
Everhart RS, McWilliams E, Maggs J, Sawicki GS, Sconiers T, Smith K, Yablon D, Butcher J, Prickett M, Bacon C, Goodman A, Gifford AH, Mayer-Hamblett N, Nichols DP, Riekert KA. Everhart RS, et al. Among authors: mayer hamblett n. J Cyst Fibros. 2024 Nov 21:S1569-1993(24)01811-3. doi: 10.1016/j.jcf.2024.11.003. Online ahead of print. J Cyst Fibros. 2024. PMID: 39578180
Qualitative understanding of experiences of people with cystic fibrosis in a treatment discontinuation trial: The QUEST study.
Maggs J, Sawicki GS, Bacon C, McWilliams E, Yablon D, Ertman B, Sweeney L, Butcher JL, Everhart RS, Prickett M, Siracusa C, Gifford AH, Mayer-Hamblett N, Nichols DP, Goodman A, Woo T, Riekert KA. Maggs J, et al. Among authors: mayer hamblett n. Contemp Clin Trials. 2025 Jan;148:107752. doi: 10.1016/j.cct.2024.107752. Epub 2024 Nov 17. Contemp Clin Trials. 2025. PMID: 39557157 Clinical Trial.
Self-reported chronic therapy use after 24-weeks of follow-up by participants who completed the simplify randomized, controlled trial.
Gifford AH, Odem-Davis K, Kloster M, O'Sullivan BP, Omlor GJ, Millard SL, Clancy JP, Sawicki GS, Riekert K, Mayer-Hamblett N, Nichols DP; SIMPLIFY Study Group. Gifford AH, et al. Among authors: mayer hamblett n. J Cyst Fibros. 2024 Sep 14:S1569-1993(24)00839-7. doi: 10.1016/j.jcf.2024.08.008. Online ahead of print. J Cyst Fibros. 2024. PMID: 39278759
Impact of Discontinuing Both Hypertonic Saline and Dornase Alfa after Elexacaftor-Tezacaftor-Ivacaftor in Cystic Fibrosis.
Mayer-Hamblett N, Gifford AH, Kloster M, Russell R, Braun AT, Gibson RL, Hoppe JE, Jain R, Linnemann RW, Liou TG, Lysinger J, Milla C, Riekert KA, Sawicki GS, Young J, Nichols D. Mayer-Hamblett N, et al. Ann Am Thorac Soc. 2024 Nov;21(11):1507-1515. doi: 10.1513/AnnalsATS.202404-366OC. Ann Am Thorac Soc. 2024. PMID: 39041864 Clinical Trial.
The effect of discontinuing hypertonic saline or dornase alfa on mucociliary clearance in elexacaftor/tezacaftor/ivacaftor treated people with cystic fibrosis: The SIMPLIFY-MCC Study.
Donaldson SH, Corcoran TE, Pilewski JM, Laube BL, Mogayzel P, Ceppe A, Wu J, Zeman K, Rowe SM, Nichols DP, Gifford AH, Bennett WD, Mayer-Hamblett N; SIMPLIFY MCC Study teams. Donaldson SH, et al. Among authors: mayer hamblett n. J Cyst Fibros. 2024 May;23(3):457-460. doi: 10.1016/j.jcf.2024.02.003. Epub 2024 Feb 13. J Cyst Fibros. 2024. PMID: 38355350 Clinical Trial.
132 results